Immunology
Human rotavirus vaccine
Brand: Rotarix®
PBAC's latest decision on Human rotavirus vaccine: Recommended with restriction (2006). Considered for prevention of rotavirus gastroenteritis in infants and children.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
2006 → 2006
Eligible population infants and children
Therapy area Immunology Line of therapy Not applicable Evidence base RCT Primary endpoint Other Comparator placebo (standard medical management) Economic model Cost-minimisation Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.